The bank raised its price target to $220 from $160, citing 'sold out' high-bandwidth memory as a key catalyst for future growth.
FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
The multi-year partnership is expected to generate tens of billions in revenue, challenging Nvidia's market dominance.
Ascendiant Capital Markets reiterates a 'Buy' rating, citing significant undervaluation and projecting a potential 1,460% upside for the e-commerce firm.
The fund, BGTF II, is now the world's largest private fund dedicated to clean energy and decarbonization, signaling strong investor confidence.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
The China-based education firm's shares plummeted to an all-time low without any immediate news, deepening concerns over its financial stability and exchange listing.